The National Comprehensive Cancer Network has issued updates to the primary and second-line therapy options for the treatment of Hodgkin lymphoma.
The American Society for Radiation Oncology has provided an update to its clinical guideline for palliative-intent radiation therapy in patients with lung cancer, recommending concurrent chemotherapy for some patients with stage III disease.
ASCO Issues New Guidelines for Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer
The American Society of Clinical Oncology has released new guidelines to address abiraterone or docetaxel with androgen-deprivation therapy for metastatic prostate cancer that has not been treated with testosterone-lowering agents.
The National Comprehensive Cancer Network has issued updated guidelines for average-risk and high-risk colorectal cancer screening.
International Workshop on CLL Revises Consensus Guideline Criteria for Prognostic Indicators, Response Assessments
Major advances in the biology and treatment of patients with CLL have prompted the International Workshop on CLL to evaluate and revise the criteria for their consensus guideline in this disease setting.
The National Comprehensive Cancer Network has published updates to their guidelines for acute lymphoblastic leukemia, which include new treatment options for Ph-positive, Ph-negative, and relapsed or refractory disease.
Results of a large study supported by the National Cancer Institute found that patients who survived testicular cancer are at a higher risk of developing heart disease.
The American Society for Radiation Oncology has issued a clinical guideline for the use of whole-breast radiation therapy that expands the eligibility criteria for hypofractionated therapy.
The American College of Physicians has issued an updated guidance statement recommending an HbA1c level between 7% and 8% in most patients with type 2 diabetes.
The National Comprehensive Cancer Network has updated their guidelines for the treatment of ovarian cancer, including therapy for stage II-IV disease and persistent disease.